Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis : a multicenter cohort study
© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society..
BACKGROUND: There is a lack of data on combined radiotherapy (RT) and cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) risk factors and toxicity. This study aimed to assess the incidence of and risk factors for non-hematologic toxicities in patients treated with combined RT and CDK4/6i using dose-volume parameter analysis.
METHODS: We conducted a retrospective multicenter cohort study of patients with metastatic breast cancer receiving RT within 14 days of CDK4/6i use. The endpoint was non-hematologic toxicities. Patient characteristics and RT treatment planning data were compared between the moderate or higher toxicities (≥ grade 2) group and the non-moderate toxicities group.
RESULTS: Sixty patients were included in the study. CDK4/6i was provided at a median daily dose of 125 mg and 200 mg for palbociclib and abemaciclib, respectively. In patients who received concurrent RT and CDK4/6i (N = 29), the median concurrent prescribed duration of CDK4/6i was 14 days. The median delivered RT dose was 30 Gy and 10 fractions. The rate of grade 2 and 3 non-hematologic toxicities was 30% and 2%, respectively. There was no difference in toxicity between concurrent and sequential use of CDK4/6i. The moderate pneumonitis group had a larger lung V20 equivalent dose of 2 Gy per fraction and planning target volume than the non-moderate pneumonitis group.
CONCLUSIONS: Moderate toxicities are frequent with combined RT and CDK4/6i. Caution is necessary concerning the combined RT and CDK4/6i. Particularly, reducing the dose to normal organs is necessary for combined RT and CDK4/6i.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Breast cancer (Tokyo, Japan) - 30(2023), 2 vom: 17. März, Seite 282-292 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kawamoto, Terufumi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.02.2023 Date Revised 27.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12282-022-01422-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350405948 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350405948 | ||
| 003 | DE-627 | ||
| 005 | 20231226044920.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12282-022-01422-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350405948 | ||
| 035 | |a (NLM)36528759 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kawamoto, Terufumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis |b a multicenter cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2023 | ||
| 500 | |a Date Revised 27.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society. | ||
| 520 | |a BACKGROUND: There is a lack of data on combined radiotherapy (RT) and cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) risk factors and toxicity. This study aimed to assess the incidence of and risk factors for non-hematologic toxicities in patients treated with combined RT and CDK4/6i using dose-volume parameter analysis | ||
| 520 | |a METHODS: We conducted a retrospective multicenter cohort study of patients with metastatic breast cancer receiving RT within 14 days of CDK4/6i use. The endpoint was non-hematologic toxicities. Patient characteristics and RT treatment planning data were compared between the moderate or higher toxicities (≥ grade 2) group and the non-moderate toxicities group | ||
| 520 | |a RESULTS: Sixty patients were included in the study. CDK4/6i was provided at a median daily dose of 125 mg and 200 mg for palbociclib and abemaciclib, respectively. In patients who received concurrent RT and CDK4/6i (N = 29), the median concurrent prescribed duration of CDK4/6i was 14 days. The median delivered RT dose was 30 Gy and 10 fractions. The rate of grade 2 and 3 non-hematologic toxicities was 30% and 2%, respectively. There was no difference in toxicity between concurrent and sequential use of CDK4/6i. The moderate pneumonitis group had a larger lung V20 equivalent dose of 2 Gy per fraction and planning target volume than the non-moderate pneumonitis group | ||
| 520 | |a CONCLUSIONS: Moderate toxicities are frequent with combined RT and CDK4/6i. Caution is necessary concerning the combined RT and CDK4/6i. Particularly, reducing the dose to normal organs is necessary for combined RT and CDK4/6i | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adverse events | |
| 650 | 4 | |a Combined modality therapy | |
| 650 | 4 | |a Palliation | |
| 650 | 4 | |a Radiation therapy | |
| 650 | 4 | |a Safety | |
| 650 | 7 | |a Cyclin-Dependent Kinase Inhibitor p18 |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase 4 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase 6 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a CDK4 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 700 | 1 | |a Shikama, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Imano, Nobuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kubota, Hikaru |e verfasserin |4 aut | |
| 700 | 1 | |a Kosugi, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Sekii, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Kazunari |e verfasserin |4 aut | |
| 700 | 1 | |a Naoi, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazawa, Kazunari |e verfasserin |4 aut | |
| 700 | 1 | |a Hirano, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tonari, Ayako |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Tetsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Nobue |e verfasserin |4 aut | |
| 700 | 1 | |a Araki, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Naoki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer (Tokyo, Japan) |d 1994 |g 30(2023), 2 vom: 17. März, Seite 282-292 |w (DE-627)NLM109487133 |x 1880-4233 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:2 |g day:17 |g month:03 |g pages:282-292 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12282-022-01422-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 2 |b 17 |c 03 |h 282-292 | ||